Biosimilars approved for psoriasis treatment in Europe

Author:

Milidrag Ardea,Lačković Maja,Dimić Ivana,Gutić Medo,Radević SvetlanaORCID,Ravić-Nikolić AnaORCID

Abstract

In recent decades, biologics have emerged as pivotal components in the therapeutic armamentarium, revolutionizing the management of various diseases, including chronic inflammatory skin disorder, the psoriasis. Biosimilars, biological formulations designed to closely mimic but not replicate existing reference biologic drugs, have heralded a seismic shift in healthcare delivery, promising equitable access to innovative therapies while fostering competition in the pharmaceutical market. The advent of biosimilars has democratized access to effective treatments, alleviating the financial burden on healthcare systems and patients alike, particularly pertinent for conditions like psoriasis, notorious for their exorbitant treatment costs. However, despite their widespread adoption and significant promise, significant challenges remain, requiring ongoing research to comprehensively examine their clinical efficacy, safety profiles, and long-term outcomes. This review aims to present all the biosimilars approved so far in Europe. Biosimilars represent a transformative force in modern healthcare, but their optimal integration requires careful monitoring, robust pharmacovigilance mechanisms, and ongoing research initiatives to ensure patient safety, build trust among healthcare providers, and maximize treatment efficacy for individuals struggling with psoriasis and other chronic diseases.

Publisher

Centre for Evaluation in Education and Science (CEON/CEES)

Reference52 articles.

1. Carrascosa JM, Jacobs I, Petersel D, et al. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb) 2018; 8: 173-94;

2. Reynolds KA, Pithadia DJ, Lee EB, et al. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? a review. Expert Opin Drug Saf 2020; 19: 459-66;

3. Sciberras J, Zammit R, Vella Bonanno P, et al. The European framework for intellectual property rights for biological medicines. GaBI J 2021; 10: 172-83;

4. European Medicines Agency. Biosimilar medicines: Overview. Amsterdam: European Medicines Agency, 2024. (https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview);

5. Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe. Mol: Pro Pharma Communications International, 2024. (https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe);

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3